Epidermal growth factor (EGF) gene polymorphism, gastroesophageal reflux disease (GERD), and esophageal adenocarcinoma (EAC) risk No significant financial relationships to disclose. This is an ASCO ...
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, ...
The phosphoinositide 3-kinase regulatory subunit p85α is a key regulator of kinase signaling and is frequently mutated in cancers. In the present study, we showed that in addition to weakening the ...
Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject ...
Platform Study to Evaluate Mirdametinib as a Combination Therapy with Fulvestrant in Patients with ER+ Metastatic Breast Cancer and as a Monotherapy in Patients with Advanced Solid Tumors Harboring ...
Blood test provides simple way to test patients comprehensively for tumor alterations that drive selection of targeted therapies, now including ENHERTU The approval means that Guardant360 CDx, a next ...
Hairy-cell leukemia (HCL) is a rare, indolent neoplasm of mature B cells with hairlike surface projections that circulate in the blood and preferentially infiltrate the bone marrow and spleen. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback